Prognostic Value of MicroRNAs in Coronary Artery Diseases: A Meta-Analysis

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2018 May 12

PMID 29749132

Citations 9

Authors

Ji Suk Kim

Kyoungjune Pak

Tae Sik Goh

Dae Cheon Jeong

Myoung Eun Han

Jihyun Kim

Sae Ock Oh

Chi Dae Kim

Yun Hak Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Coronary artery diseases (CADs) are the leading causes of death in the world. Recent studies have reported that differentially expressed microRNAs (miRNAs) are associated with prognosis or major adverse cardiac events (MACEs) in CAD patients. In a previous meta-analysis, the authors made serious mistakes that we aimed to correct through an updated systematic review and meta-analysis of the prognostic value of altered miRNAs in patients with CADs.

Materials And Methods: We performed a systematic search of MEDLINE (from inception to May 2017) and EMBASE (from inception to May 2017) for English-language publications. Studies of CADs with results on miRNAs that reported survival data or MACEs were included. Data were extracted from each publication independently by two reviewers.

Results: After reviewing 515 articles, a total eight studies were included in this study. We measured pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of miRNA 133a with a fixed-effect model (pooled HR, 2.35; 95% CI, 1.56-3.55). High expression of miRNA 133a, 208b, 126, 197, 223, and 122-5p were associated with high mortality. Additionally, high levels of miRNA 208b, 499-5p, 134, 328, and 34a were related with MACEs.

Conclusion: The present study confirmed that miRNA 133a, which was associated with high mortality in CAD patients, holds prognostic value in CAD. More importantly, this study corrected issues raised against a prior meta-analysis and provides accurate information.

Citing Articles

Protective Effects of NaHS/miR-133a-3p on Lipopolysaccharide-Induced Cardiomyocytes Injury.

Jin Y, Huang A, Yu M, Ye W, Hu X, Wang H J Toxicol. 2023; 2023:2566754.

PMID: 38106638 PMC: 10723929. DOI: 10.1155/2023/2566754.

Atherosclerosis and Its Related Laboratory Biomarkers.

Della Corte V, Todaro F, Cataldi M, Tuttolomondo A Int J Mol Sci. 2023; 24(21).

PMID: 37958528 PMC: 10649778. DOI: 10.3390/ijms242115546.

Dysregulation of Inflammation, Oxidative Stress, and Glucose Metabolism-Related Genes and miRNAs in Visceral Adipose Tissue of Women with Type 2 Diabetes Mellitus.

Wroblewski A, Strycharz J, Oszajca K, Czarny P, Swiderska E, Matyjas T Med Sci Monit. 2023; 29:e939299.

PMID: 37422695 PMC: 10340125. DOI: 10.12659/MSM.939299.

The Profile of Circulating Blood microRNAs in Outpatients with Vulnerable and Stable Atherosclerotic Plaques: Associations with Cardiovascular Risks.

Rozhkov A, Shchekochikhin D, Ashikhmin Y, Mitina Y, Evgrafova V, Zhelankin A Noncoding RNA. 2022; 8(4).

PMID: 35893230 PMC: 9326687. DOI: 10.3390/ncrna8040047.

microRNAs signatures as potential biomarkers of structural cardiotoxicity in human-induced pluripotent stem-cell derived cardiomyocytes.

Gryshkova V, Lushbough I, Palmer J, Burrier R, Delaunois A, Donley E Arch Toxicol. 2022; 96(7):2033-2047.

PMID: 35488128 DOI: 10.1007/s00204-022-03280-8.

References

Cao W, Guo Q, Zhang T, Zhong D, Yu Q . Prognostic value of microRNAs in acute myocardial infarction: A systematic review and meta-analysis. Int J Cardiol. 2015; 189:79-84. DOI: 10.1016/j.ijcard.2015.04.055. View

Huang W . MicroRNAs: Biomarkers, Diagnostics, and Therapeutics. Methods Mol Biol. 2017; 1617:57-67. DOI: 10.1007/978-1-4939-7046-9_4. View

Wu Z, Wang C, Xiang R, Liu X, Ye S, Yang X . Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer. 2012; 12:51. PMC: 3297527. DOI: 10.1186/1471-2407-12-51. View

Olivieri F, Antonicelli R, Spazzafumo L, Santini G, Rippo M, Galeazzi R . Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction. Int J Cardiol. 2014; 172(2):e276-8. DOI: 10.1016/j.ijcard.2013.12.203. View

Ke-Gang J, Zhi-Wei L, Xin Z, Jing W, Ping S, Xue-Jing H . Evaluating Diagnostic and Prognostic Value of Plasma miRNA133a in Acute Chest Pain Patients Undergoing Coronary Angiography. Medicine (Baltimore). 2016; 95(17):e3412. PMC: 4998688. DOI: 10.1097/MD.0000000000003412. View

He F, Lv P, Zhao X, Wang X, Ma X, Meng W . Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol Cell Biochem. 2014; 394(1-2):137-44. DOI: 10.1007/s11010-014-2089-0. View

Wang J, Yu M, Guan S, Zhang G, Wang J, Cheng Y . Prognostic significance of microRNA-100 in solid tumors: an updated meta-analysis. Onco Targets Ther. 2017; 10:493-502. PMC: 5271396. DOI: 10.2147/OTT.S122774. View

Kim Y, Bae J, Kim I, Chang C, Oh S, Kim C . SIRT1 prevents pulmonary thrombus formation induced by arachidonic acid via downregulation of PAF receptor expression in platelets. Platelets. 2016; 27(8):735-742. DOI: 10.1080/09537104.2016.1190005. View

Widera C, Gupta S, Lorenzen J, Bang C, Bauersachs J, Bethmann K . Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011; 51(5):872-5. DOI: 10.1016/j.yjmcc.2011.07.011. View

10.

Chan D, Ng L . Biomarkers in acute myocardial infarction. BMC Med. 2010; 8:34. PMC: 2898678. DOI: 10.1186/1741-7015-8-34. View

11.

Lv P, Zhou M, He J, Meng W, Ma X, Dong S . Circulating miR-208b and miR-34a are associated with left ventricular remodeling after acute myocardial infarction. Int J Mol Sci. 2014; 15(4):5774-88. PMC: 4013595. DOI: 10.3390/ijms15045774. View

12.

Kim Y, Lee S, Seo K, Bae J, Park S, Kim E . PAF enhances MMP-2 production in rat aortic VSMCs via a β-arrestin2-dependent ERK signaling pathway. J Lipid Res. 2013; 54(10):2678-86. PMC: 3770081. DOI: 10.1194/jlr.M037176. View

13.

Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y . miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2011; 127(12):2804-14. DOI: 10.1002/ijc.25284. View

14.

Ha M, Kim V . Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509-24. DOI: 10.1038/nrm3838. View

15.

Gidlof O, Smith J, Miyazu K, Gilje P, Spencer A, Blomquist S . Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc Disord. 2013; 13:12. PMC: 3598930. DOI: 10.1186/1471-2261-13-12. View

16.

Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M . Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet. 2011; 4(4):446-54. DOI: 10.1161/CIRCGENETICS.110.958975. View

17.

Heneghan H, Miller N, Kerin M . Role of microRNAs in obesity and the metabolic syndrome. Obes Rev. 2009; 11(5):354-61. DOI: 10.1111/j.1467-789X.2009.00659.x. View

18.

Liu N, Bezprozvannaya S, Williams A, Qi X, Richardson J, Bassel-Duby R . microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008; 22(23):3242-54. PMC: 2600761. DOI: 10.1101/gad.1738708. View

19.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. PMC: 10790329. DOI: 10.1016/S0140-6736(12)61728-0. View

20.

DAlessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla P . Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010; 31(22):2765-73. PMC: 2980809. DOI: 10.1093/eurheartj/ehq167. View